Thyroid-Stimulating Hormone (TSH) Immunofluorescence Assay: Comprehensive Thyroid Health Management with Integrated FT4/FT3 Testing

TSH-FT4-FT3: The Golden Triad for Thyroid Function Assessment
Thyroid-Stimulating Hormone (TSH), the central regulator of the pituitary-thyroid axis, serves as the "first signal" for thyroid dysfunction. Free Thyroxine (FT4) and Free Triiodothyronine (FT3), which directly reflect the bioactivity of thyroid hormones, form a critical diagnostic triad with TSH. Combined testing of these three biomarkers enables comprehensive evaluation of thyroid status, precise differentiation of primary, secondary, and subclinical disorders, and robust support for clinical decision-making.

Evidence-Based Clinical Applications

1. Precise Classification of Thyroid Dysfunction：

     TSH + FT4 Synergy: Elevated TSH with reduced FT4 confirms primary hypothyroidism (sensitivity >98%), while suppressed TSH with elevated FT4 indicates thyrotoxicosis (e.g., Graves' disease).

    TSH + FT3 Dynamic Monitoring: FT3 demonstrates higher sensitivity for early hyperthyroidism detection. TSH <0.1 mIU/L combined with FT3 >6.5 pmol/L Facilitates rapid identification of T3-predominant thyrotoxicosis, minimizing missed diagnoses.

2. Neonatal Screening for Congenital Hypothyroidism and Resistance Syndromes：

    Congenital Hypothyroidism: TSH ≥10 mIU/L with FT4 <12 pmol/L confirms Diagnosis.

Thyroid Hormone Resistance (RTH): Elevated TSH with normal FT4 necessitates RTH evaluation to prevent misdiagnosis.

3. Personalized Treatment Monitoring：

    Hyperthyroidism Management: Concurrent TSH, FT3, and FT4 testing dynamically tracks antithyroid drug efficacy (targets: TSH 0.4-2.0 mIU/L, FT4 10-20 pmol/L), avoiding overtreatment-induced hypothyroidism.

    Hypothyroidism Therapy: Levothyroxine dosage optimization integrates TSH (target: 0.5-3.0 mIU/L) and FT4 levels (12-22 pmol/L) for precise hormone replacement.

4. Comprehensive Thyroid Management in Pregnancy：

    Overt Hypothyroidism: TSH ≥2.5 mIU/L with FT4 below trimester-specific reference ranges warrants immediate intervention.

Isolated Hypothyroxinemia: Normal TSH with low FT4 may indicate gestational risks, necessitating TPO antibody evaluation.

5. Differential Diagnosis of Complex Endocrine Disorders：

Central Hypothyroidism: Normal/low TSH with reduced FT4.

Subclinical Thyroid Disease: Abnormal TSH with normal FT4/FT3, requiring long-term follow-up.

Non-Thyroidal Illness Syndrome (NTIS): Markedly low FT3 with normal TSH suggests systemic critical illness.

aehealth Immunofluorescence Platform: Multi-Parameter Testing, Unmatched Efficiency

Lamuno X: 10 Channels Operation

Lamuno Pro: 12 Independent Operation Channels

Lamuno Plus:Multi Scenes Usage 

Simultaneous Multi-Parameter Detection: TSH, FT4, and FT3 results in 15 minutes with a single test.

Linear Range:

TSH 0.1-100 mIU/mL, FT4 0.3-100 pmol/L, FT3 0.4-50 pmol/L, covering screening to critical care needs.

Superior Performance: Sensitivity of 0.01 mIU/mL (TSH) and 0.5 pmol/L (FT4/FT3);

Smart Analytics: Auto-adjusted reference intervals for pregnancy and age groups, with AI-driven clinical insights for streamlined decision-making.

Empowering Precision Medicine, Safeguarding Thyroid Health
Aehealth revolutionizes thyroid diagnostics by integrating TSH, FT4, and FT3 testing into a single platform. This all-in-one solution enhances diagnostic accuracy, reduces clinical errors, and supports end-to-end patient management—from screening to long-term monitoring—enabling healthcare providers to deliver superior thyroid care.